Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) EVP Neena M. Patil sold 5,000 shares of the firm's stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total value of $548,250.00. Following the sale, the executive vice president now owns 36,629 shares in the company, valued at approximately $4,016,369.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Jazz Pharmaceuticals Trading Up 1.2 %
NASDAQ:JAZZ opened at $111.21 on Wednesday. The business's 50-day moving average is $115.56 and its two-hundred day moving average is $120.62. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.27 and a quick ratio of 1.90. Jazz Pharmaceuticals plc has a 12 month low of $103.01 and a 12 month high of $146.70. The firm has a market capitalization of $7.01 billion, a PE ratio of 22.93, a price-to-earnings-growth ratio of 1.53 and a beta of 0.63.
Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The company had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1.01 billion. Research analysts predict that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
From Banyan Hill Publishing | Ad
If you think AI is big, then you have got to check out something I call Imperium…
By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Watch my video for all of the details
Several hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new stake in shares of Jazz Pharmaceuticals during the third quarter worth about $611,000. Commonwealth Equity Services LLC increased its position in shares of Jazz Pharmaceuticals by 10.6% during the third quarter. Commonwealth Equity Services LLC now owns 10,073 shares of the specialty pharmaceutical company's stock worth $1,304,000 after acquiring an additional 962 shares during the last quarter. Forsta AP Fonden increased its position in shares of Jazz Pharmaceuticals by 15.2% during the third quarter. Forsta AP Fonden now owns 22,000 shares of the specialty pharmaceutical company's stock worth $2,848,000 after acquiring an additional 2,900 shares during the last quarter. Strs Ohio increased its position in shares of Jazz Pharmaceuticals by 4.4% during the third quarter. Strs Ohio now owns 14,119 shares of the specialty pharmaceutical company's stock worth $1,827,000 after acquiring an additional 593 shares during the last quarter. Finally, Advisor Partners II LLC purchased a new stake in shares of Jazz Pharmaceuticals during the third quarter worth about $231,000. 89.14% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several research firms have recently issued reports on JAZZ. HC Wainwright restated a "buy" rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, May 3rd. Truist Financial restated a "buy" rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Cantor Fitzgerald restated an "overweight" rating and set a $180.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. UBS Group cut their target price on Jazz Pharmaceuticals from $135.00 to $131.00 and set a "neutral" rating on the stock in a research report on Friday, March 1st. Finally, Barclays cut their target price on Jazz Pharmaceuticals from $230.00 to $200.00 and set an "overweight" rating on the stock in a research report on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $192.75.
Get Our Latest Stock Analysis on Jazz Pharmaceuticals
About Jazz Pharmaceuticals
(
Get Free Report)
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
